Argenx
Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.
DitchCarbon Score
How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Argenx's score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Argenx's reported carbon emissions
In 2024, Argenx reported total carbon emissions of approximately 231,769,000 kg CO2e. This figure includes 3,788,000 kg CO2e from Scope 1 emissions, 534,000 kg CO2e from Scope 2 emissions (market-based), and a significant 227,447,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 183,781,000 kg CO2e) and business travel (approximately 13,340,000 kg CO2e). In 2023, Argenx's total emissions were approximately 433,353,000 kg CO2e, with Scope 1 emissions at 378,000 kg CO2e, Scope 2 emissions at 189,000 kg CO2e (market-based), and Scope 3 emissions reaching about 432,786,000 kg CO2e. The largest contributors to Scope 3 emissions were again purchased goods and services (around 378,956,000 kg CO2e) and capital goods (approximately 28,054,000 kg CO2e). Despite the substantial emissions figures, Argenx has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded emissions data from a parent organisation, and all reported figures are derived directly from Argenx SE. Overall, Argenx's emissions profile highlights the significant impact of Scope 3 emissions, particularly from their supply chain and operational activities, underscoring the need for comprehensive strategies to address these challenges in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 378,000 | 0,000,000 |
| Scope 2 | 189,000 | 000,000 |
| Scope 3 | 432,786,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
